Furthermore, this indicates that an inhibitor of the MK2 pathway, small molecule—MK2.III can act as a chemosensitizer when used in combination with DNA-damaging agents, particularly etoposide, making NCI-H69 lung cancer cells sensitive to chemotherapeutic drug for up to ~ 45% compared to single usage of the drug. The gene discussed is MAPKAPK2; the disease is lung carcinoma.